February 19, 2025

Bharat Biotech’s Dr. Krishna M. Ella Assumes Presidency of Indian Vaccine Manufacturers Association

Recently, there was a major change in the leadership of the Indian Vaccine Manufacturers Association (IVMA). Bharat Biotech’s executive chairman and co-founder, Krishna Ella, took over as president of the association for a two-year term beginning in April 2024. This change is a turning point for the association, demonstrating its dedication to promoting cooperation in the vaccine production industry and expanding global health via immunizations.

The appointment of Mr. Ella comes after Adar C. Poonawala, who led IVMA as president from 2019 until March 2024. In addition to Mr. Ella, T. Srinivas, CFO of Bharat Biotech, becomes treasurer, and Mahima Datla, managing director of Biological E, assumes the position of vice president. As the Director General of IVMA, Dr. Harshavardhan continues to lead and maintain continuity within the association.

Mr. Ella stated in a news release from Bharat Biotech that he is committed to IVMA’s goal of guaranteeing that everyone has access to life-saving vaccines. He underlined the significance of equity, sustainability, and innovation in advancing IVMA’s and its members’ shared mission. In addition to highlighting the vital role vaccines play in maintaining global public health, Mr. Ella’s remark demonstrates his dedication to furthering IVMA’s goals while serving as president.

Mr. Ella’s vision for IVMA places a strong emphasis on aiding the public health activities of African countries. He emphasized the significance of harmonizing rules and policies with global norms established by agencies such as the US Food and Drug Administration (USFDA) and the World Health Organization (WHO). In addition to increasing competitiveness internationally, this alignment solidifies India’s standing as the world’s preeminent provider of preventive healthcare.

Speaking on behalf of IVMA, Dr. Harshavardhan highlighted the value of Mr. Ella’s leadership in navigating the intricate issues facing the vaccine sector in the twenty-first century. He also commended Mr. Ella’s knowledge and entrepreneurial zeal. The backing of Dr. Harshavardhan indicates IVMA’s faith in Mr. Ella’s leadership and his calculated approach to advancing the association’s goals.

The goal of IVMA is to represent the interests of all Indian private sector human vaccine makers, not just certain businesses. This involves attending to industry concerns about advancement, profitability, regulatory pathways, and audit and inspection-related issues. IVMA’s attempts to maintain regulatory compliance and streamline operations are contingent upon its collaboration with national regulatory agencies, such as the Central Drugs Standard and Control Organization (CDSCO).

In order to promote good change in the vaccine manufacturing landscape, proactive involvement, strategic planning, and group action are the hallmarks of the recent leadership turnover within IVMA. Under Mr. Ella’s leadership, IVMA will benefit from a plethora of experience, creativity, and a global viewpoint, setting the organization up for future expansion and influence in the promotion of public health through immunization programs.

Under Mr. Ella’s direction, IVMA is starting a new chapter that will involve cooperative alliances, support for business interests, and a redoubled commitment to tackling global health issues. IVMA’s next two years are going to be extremely important as it continues to pursue its goal of providing affordable, high-quality vaccines to as many people as possible.

SOURCE:

THE HINDU

 

Tags

Facebook
WhatsApp
Telegram
LinkedIn
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x